Design to Implementation Study for Development and Patient Validation of Paper-Based Toehold Switch Diagnostics
June 17th, 2022
3.3K views
Access to decentralized, low-cost, and high-capacity diagnostics that can be deployed into the community for decentralized testing is critical for combating global health crises. This manuscript describes how to build paper-based diagnostics for viral RNA sequences that can be detected with a portable optical reader.
Overview
This study presents a protocol for designing and validating paper-based molecular diagnostics for viral RNA detection. The approach utilizes a cell-free toehold switch sensor that can be tailored to detect various nucleic acid sequences, making it a versatile tool for decentralized diagnostics.
Key Study Components
Area of Science
- Diagnostics
- Molecular Biology
- Viral Detection
Background
- Decentralized diagnostics are essential for addressing global health challenges.
- Paper-based diagnostics offer a low-cost and portable solution.
- Cell-free toehold switch sensors can detect a wide range of nucleic acids.
- Previous applications include diagnostics for Ebola, norovirus, and SARS-CoV-2.
Purpose of Study
- To provide a detailed protocol for developing paper-based diagnostics.
- To demonstrate the sensitivity and specificity of the toehold switch sensors.
- To facilitate the use of these diagnostics in decentralized settings.
Methods Used
- Designing toehold switches using target RNA sequences.
- Performing PCR and analyzing products via agarose gel electrophoresis.
- Using a portable plate reader for absorbance measurements.
- Conducting sensitivity analyses with serial dilutions of target RNA.
Main Results
- Successful construction of toehold switches demonstrated by PCR results.
- Rapid response of sensor 27B compared to others.
- High sensitivity achieved for clinically relevant RNA concentrations.
- Potential for application in various decentralized healthcare settings.
Conclusions
- Paper-based diagnostics can effectively detect viral RNA.
- The protocol allows for customization based on user needs.
- These diagnostics can enhance healthcare accessibility in resource-limited areas.
Frequently Asked Questions
What is the main advantage of paper-based diagnostics?
They are low-cost, portable, and can be deployed in decentralized settings.
How can the toehold switch sensors be customized?
Users can design them to target specific nucleic acid sequences based on their needs.
What types of viruses can be detected using this method?
The method can be adapted to detect various viruses, including Zika, Ebola, and SARS-CoV-2.
What is the role of the portable optical reader?
It measures the absorbance of the reactions, indicating the presence of target RNA.
Is prior experience in molecular biology required to use this protocol?
Some background in molecular biology is helpful, but the protocol is designed to be user-friendly.
How sensitive are the toehold switch sensors?
They can detect clinically relevant concentrations of nucleic acids with high sensitivity.
Executive Industry Relevance
This protocol enables the design and validation of low-cost, paper-based toehold switch diagnostics for viral RNA detection, offering a decentralized testing solution with performance comparable to RT-qPCR. It supports early-stage target validation by providing a rapid, sensitive platform for assessing nucleic acid biomarkers in patient samples. The approach reduces development burden and expands diagnostic access in resource-limited settings, aligning with biopharma needs for scalable, deployable screening tools.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses through rapid design and screening of nucleic acid sensors against viral targets.
- Operational Value: Supports functional validation of candidate biomarkers using patient-derived samples in a low-burden format.
- Predictive Value: Provides quantitative absorbance readouts that correlate with clinical positivity, aiding in target de-risking.
Screening & Assay Development
- Scientific Value: Generates standardized, reproducible cell-free reactions suitable for high-sensitivity detection of low-abundance RNA targets.
- Operational Value: Utilizes inexpensive, lyophilizable components and a portable optical reader for point-of-care adaptability.
- Scalability: Facilitates assay optimization through serial dilution and triplicate testing to establish limits of detection.
Translational & Preclinical Research
- Translational Continuity: Bridges discovery and preclinical validation by enabling direct testing of patient samples alongside gold-standard RT-qPCR.
- Biomarker Alignment: Supports evaluation of nucleic acid-based biomarkers with clinical relevance, as demonstrated in Zika virus patient cohorts.
- Risk Mitigation: Allows iterative optimization of sensor specificity and sensitivity before advancing to larger validation studies.
Pipeline & Workflow Integration
The method fits within the early discovery continuum, supporting hypothesis-driven target identification and assay readiness for downstream screening campaigns.
- Discovery Biology: Enables rapid prototyping of sensors to test target engagement and pathway-specific RNA signatures.
- Screening: Delivers quantitative, colorimetric outputs compatible with plate reader-based throughput and hit confirmation.
- Analytics: Provides measurable signal-to-noise ratios and limit-of-determination data essential for assay qualification.
- Translational Research: Validates sensor performance in clinically relevant matrices, ensuring relevance to human disease contexts.
- Enterprise Reuse: Establishes a modular platform adaptable to emerging targets across therapeutic areas without reformatting core workflows.
Operational & Enterprise Impact
- Scientific Value: Enhances target validation confidence through direct correlation of sensor signal with clinical sample status.
- Operational Value: Ensures reproducibility via standardized reaction assembly, controlled incubation, and normalized optical readouts.
- Strategic Value: Reduces dependency on centralized labs, enabling faster go/no-go decisions in early discovery.
- Portfolio Impact: Supports risk-adjusted prioritization of targets based on detectable biomarker expression in patient samples.
Implementation Considerations
- Requires familiarity with molecular cloning, in vitro transcription, and nucleic acid handling.
- Dependent on access to thermocyclers, spectrophotometers, and plate readers for reaction setup and analysis.
- Necessitates cross-team agreement on threshold settings for positivity calls to ensure consistent interpretation.
- Involves optimization steps for sensor design, primer performance, and background signal minimization.
- Limited by the need for empirical testing of each switch variant to rule out cross-reactivity and ensure specificity.
Biopharma FAQs
Why does signal-to-noise ratio matter in toehold switch validation?
A high on/off signal ratio indicates specific target engagement with minimal background, which is critical for distinguishing true positives in complex samples. This metric was used to identify sensor 27B as the optimal candidate due to its superior specificity over other switches. Reliable signal separation supports confident biomarker detection in patient-derived materials.
How does NASBA amplification improve detection limits in this workflow?
NASBA pre-amplification increases the concentration of target RNA, enabling detection of as few as 124 molecules per microliter when coupled with the toehold switch sensor. This amplification step was essential for achieving clinically relevant sensitivity in patient sample testing. It bridges the gap between low-abundance biomarkers and the sensor’s dynamic range.
What role does the PLUM portable plate reader play in assay execution?
The PLUM reader measures absorbance at 570 nm over time to capture the colorimetric response of the paper-based reactions, enabling real-time monitoring of switch activation. It was used to track reaction kinetics and determine positivity based on exceeding a predefined threshold. This portable readout supports decentralized testing without requiring laboratory infrastructure.
Why is reproducibility emphasized before advancing to patient trials?
Reproducibility across biological triplicates ensures that sensor performance is not due to stochastic variation or reagent inconsistency, which is essential for generating trustworthy diagnostic data. The protocol stresses optimizing NASBA primer sensitivity and switch performance prior to patient sample testing. Consistent results build confidence in the assay’s reliability for clinical decision support.
What specific output determines a positive sample in the toehold switch assay?
A sample is considered positive if its colorimetric signal exceeds the threshold established from negative controls, as measured by absorbance at 570 nm over time. This threshold-based call was validated against RT-qPCR, where positivity was defined as a cycle threshold ≤ 38. The method provides a quantitative, instrument-readable output suitable for automated interpretation.
Chapters in this video
0:04
Introduction
1:07
Computational Design of Toehold Switches
2:45
Construction of Toehold Switches by PCR
3:32
Initial Screening of the Switches
5:16
NASBA Primer Screening and Sensitivity
6:55
RT-qPCR for Zika Virus Detection
8:08
Results: Evaluation of Toehold Switches for Paper-Based Zika Sensors
10:01
Conclusion
